The pharmacokinetics of subcutaneous cytosine arabinoside in patients with acute myelogenous leukaemia.
1 The pharmacokinetics of subcutaneous cytosine arabinoside were compared with bolus intravenous injection and intravenous infusion in five patients with acute myelogenous leukaemia. 2 Subcutaneous cytosine arabinoside was rapidly absorbed and then declined biexponentially with initial and terminal half-lives similar to intravenous bolus injection. 3 Cytosine arabinoside levels declined rapidly after intravenous bolus and subcutaneous bolus injection, and fell below steady state infusion levels after a mean time of 40 min (intravenous bolus) and 100 min (subcutaneous injection).
D000328:Adult; D003561:Cytarabine / Q000378:metabolism / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D006801:Humans; D007263:Infusions, Parenteral; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D007700:Kinetics; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*
D003561:Cytarabine